PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.97%
Revenue growth above 1.5x AVGO's 0.59%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
4.03%
Gross profit growth above 1.5x AVGO's 0.51%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
16.31%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
12.45%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
207.84%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
204.00%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
200.00%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
4.94%
Share count expansion well above AVGO's 0.26%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
5.32%
Slight or no buyback while AVGO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-7.43%
Dividend reduction while AVGO stands at 0.14%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
59.20%
OCF growth above 1.5x AVGO's 7.23%. David Dodd would confirm a clear edge in underlying cash generation.
136.40%
FCF growth above 1.5x AVGO's 6.62%. David Dodd would verify if the firm’s strategic investments yield superior returns.
36.04%
10Y revenue/share CAGR under 50% of AVGO's 409.54%. Michael Burry would suspect a lasting competitive disadvantage.
-23.23%
Negative 5Y CAGR while AVGO stands at 122.61%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-0.63%
Negative 3Y CAGR while AVGO stands at 60.90%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
277.93%
10Y OCF/share CAGR at 50-75% of AVGO's 441.92%. Martin Whitman might fear a structural deficiency in operational efficiency.
42.76%
5Y OCF/share CAGR at 50-75% of AVGO's 73.80%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
-5.23%
Negative 3Y OCF/share CAGR while AVGO stands at 34.25%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
8874.99%
Net income/share CAGR above 1.5x AVGO's 691.11% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
307.63%
Below 50% of AVGO's 651.30%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
365.54%
3Y net income/share CAGR above 1.5x AVGO's 66.58%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
292.02%
Below 50% of AVGO's 839.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
211.37%
5Y equity/share CAGR 1.25-1.5x AVGO's 147.32%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
153.92%
3Y equity/share CAGR at 75-90% of AVGO's 188.08%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
7.92%
Below 50% of AVGO's 1441.93%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
29.26%
Below 50% of AVGO's 71.80%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
-7.85%
Negative near-term dividend growth while AVGO invests at 38.29%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
9.79%
AR growth well above AVGO's 14.59%. Michael Burry fears inflated revenue or higher default risk in the near future.
8.75%
Inventory growth well above AVGO's 5.71%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
11.76%
Positive asset growth while AVGO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
7.81%
Positive BV/share change while AVGO is negative. John Neff sees a clear edge over a competitor losing equity.
-1.82%
We’re deleveraging while AVGO stands at 1.06%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-0.25%
Our R&D shrinks while AVGO invests at 19.53%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
3.09%
SG&A declining or stable vs. AVGO's 14.12%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.